Identification of small molecule sphingomyelin synthase inhibitors.
暂无分享,去创建一个
Renxiao Wang | Ting-bo Ding | Xiaodong Deng | Deyong Ye | Xian-cheng Jiang | Bin Lou | Yan Li | F. Lin | Yue Li | Lu Zhou | Ya Zhang | Ji-bin Dong | Xian-Cheng Jiang
[1] M. Kuo,et al. Impact of Sphingomyelin Synthase 1 Deficiency on Sphingolipid Metabolism and Atherosclerosis in Mice , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[2] Xiaodong Deng,et al. Development, Validation, and Application of a Novel Method for Mammalian Sphingomyelin Synthase Activity Measurement , 2012 .
[3] R. M. Adibhatla,et al. Tricyclodecan-9-yl-Xanthogenate (D609) Mechanism of Actions: A Mini-Review of Literature , 2011, Neurochemical Research.
[4] D. Peake,et al. Reducing Plasma Membrane Sphingomyelin Increases Insulin Sensitivity , 2011, Molecular and Cellular Biology.
[5] Renxiao Wang,et al. Molecular Modeling of the Three-Dimensional Structure of Human Sphingomyelin Synthase , 2011 .
[6] Xian-cheng Jiang,et al. Sphingomyelin biosynthesis: its impact on lipid metabolism and atherosclerosis , 2009 .
[7] J. Borén,et al. Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update , 2007 .
[8] T. Lübbers,et al. Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.
[9] Jibin Dong,et al. Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice Published, JLR Papers in Press, February 28, 2006. , 2006, Journal of Lipid Research.
[10] M. Hojjati,et al. Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice. , 2005, Biochimica et biophysica acta.
[11] Y. Hannun,et al. Prodrug Modification Increases Potassium Tricyclo[5.2.1.02,6]-decan-8-yl Dithiocarbonate (D609) Chemical Stability and Cytotoxicity against U937 Leukemia Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.
[12] Y. Hannun,et al. Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. , 2004, Experimental cell research.
[13] J. Brouwers,et al. Identification of a family of animal sphingomyelin synthases , 2004, The EMBO journal.
[14] F. Himo,et al. Mechanisms of tetrazole formation by addition of azide to nitriles. , 2002, Journal of the American Chemical Society.
[15] T. Tsuruo,et al. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel , 2002, Cancer Chemotherapy and Pharmacology.
[16] M. Tatsumi,et al. Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[17] Urtiaga,et al. A convenient strategy for the synthesis of 4,5-bis(o-haloaryl)isoxazoles , 2000, The Journal of organic chemistry.
[18] M. Kanai,et al. A Catalytic Asymmetric Strecker‐Type Reaction: Interesting Reactivity Difference between TMSCN and HCN , 2000 .
[19] A. Davies,et al. A Facile Synthesis of Substituted Phenylglycines , 2000 .